A melanocortin-4 receptor agonist did not induce significant decreases in BMI for patients with four rare genetic forms of ...

Four substudies did not meet pre-specified primary endpoints -- -- Post hoc analyses show setmelanotide achieved ...

A Phase III trial of Rhythm Pharmaceuticals’ Imcivree (setmelanotide) failed to meet its primary endpoints in four rare, ...

Rhythm Pharmaceuticals’ phase 3 EMANATE trial of setmelanotide fails to meet primary endpoints: Boston Wednesday, March 18, 2026, 18:00 Hrs [IST] Rhythm Pharmaceuticals, Inc., a ...

Editas Medicine (NASDAQ:EDIT) executives outlined the company’s in vivo CRISPR gene-editing strategy and near-term clinical ...

Rhythm Pharma (RYTM) stock drops as the company's lead asset, setmelanotide, fails in a late-stage clinical study for certain rare forms of obesity. Read more here.

Although the window for Rhythm Pharmaceuticals’ Imcivree to break out of the genetic obesity realm is quickly approaching ...

Four substudies did not meet pre-specified primary endpoints -- -- Post hoc analyses show setmelanotide achieved statistically significant BMI reductions in patients with obesity due to a heterozygous ...

Detailed price information for Rhythm Pharmaceuticals Inc (RYTM-Q) from The Globe and Mail including charting and trades.

Rhythm Pharmaceuticals said its Phase 3 trial for setmelanotide for patients with rare, genetically-driven obesities did not meet its primary endpoints.

Researchers have pinpointed a gene mutation associated with survival at high altitudes that could restore myelin to damaged ...